Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $310

Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $310

Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $300 to $310.

byBenzinga Newsdesk

December 6, 2022

1 minute read

Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $300 to $310.

Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In April

By Lisa Levin

April 27, 8:36 AM

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.

ACHR

ADT Affirms Guidance

By Benzinga Newsdesk

August 4, 6:59 AM

The Company is affirming its previously provided financial guidance for the full year 2022. Each metric shown below represents an improvement over the same measure in 2021. (in

ADT

Needham Maintains Buy on Bel Fuse, Raises Price Target to $30

By Benzinga Newsdesk

July 29, 6:42 AM

Needham analyst James Ricchiuti maintains Bel Fuse (NASDAQ:BELFB) with a Buy and raises the price target from $25 to $30.

BELFB

Livewire To Acquire Majority Equity Stake In LA Cannabis Direct-To-Consumer Delivery Company

By Vuk Zdinjak

March 7, 11:31 AM

LiveWire Ergogenics Inc. (OTCPK:LVVV) has entered into an agreement to acquire a majority equity stake in the Green Eagle Cannabis Delivery company in Los Angeles, California.

LVVV

Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $310

Related Posts

Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In April

ADT Affirms Guidance

Needham Maintains Buy on Bel Fuse, Raises Price Target to $30

Livewire To Acquire Majority Equity Stake In LA Cannabis Direct-To-Consumer Delivery Company